UDP-glucuronosyltransferase UGT1A7 catalyzes the glucuronidation of benzo(a)pyrene metabolites and other bulky aromatic compounds. Both UGT1A7 mRNA and an associated enzyme activity (benzo(a)pyrene-7,8-dihydrodioltransferase activity) are markedly increased in livers of rats treated with ␤-naphthoflavone or 4-methyl-5-pyrazinyl-3H-1,2-dithiole-3-thione (oltipraz). Nuclear runoff assays show that the effects of both inducers are primarily due to transcriptional activation. A 27-kilobase region that included the UGT1A7/ UGT1A6 promoter regions was cloned. Primer extension and RNase protection studies indicated >30 transcription start sites in five clusters between bases ؊85 and ؊40 respective to the translation start codon. There was no recognizable TATA box, but the promoter region is TA-rich. Sequence analysis revealed potential binding sites for CCAAT enhancer-binding protein, activator protein 1, and hepatic nuclear factors 1, 3, and 4, but no xenobiotic response elements or antioxidant response elements, implicated in the regulation of other genes by ␤-naphthoflavone or oltipraz, were found. A UGT1A7 gene reporter plasmid directed strong constitutive expression in transient transfection assays using primary rat hepatocytes. Treatment with 3-methylcholanthrene or oltipraz had no effect compared with similarly treated pGL3-Basic-transfected cells. These results suggest that the regulatory elements controlling xenobiotic inducibility of UGT1A7 transcription are located either 5 or 3 of bases ؊1600 to ؉54. One possibility is that the polycyclic aromatic-mediated regulation of UGT1A7 occurs via the xenobiotic response element flanking the UGT1A6 locus 7 kilobase pairs downstream.
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UDP-Glucuronosyltransferases (UGTs)
1 (EC 2.4.1.17) catalyze the reaction of UDP-glucuronic acid with substrates bearing a variety of different functional groups, including OH, NH 2 , SH 2 , and COOH. Because the glucuronides are usually less biologically active, more polar, and readily excreted from organisms, the UGTs are considered important for the general detoxification and elimination of a host of endogenous and exogenous substances, such as bilirubin, steroids, environmental pollutants, carcinogens, and dietary substances. Molecular cloning evidence indicates the existence of two large families of UGTs, UGT1 and UGT2 (1) . UGT1 family members are encoded by a unique gene complex, UGT1, which utilizes exon sharing to generate Ն12 isozyme forms with homologous but unique amino-terminal (Ϸ287 amino acids) and identical carboxyl-terminal sequences (245 amino acids) (2, 3) . UGT2 family members, in contrast, appear to be encoded by independent genes. Each UGT exhibits its own unique profile of substrate and tissue specificity and regulation by exposure to endogenous or xenobiotic compounds (1) .
A recent focus of our studies has been the UGT isozymes responsible for the glucuronidating activity of rat liver microsomes toward benzo(a)pyrene metabolites. Benzo(a)pyrene is a prototype of the polycyclic aromatic hydrocarbons (PAHs), a class of carcinogens introduced into the environment from the partial combustion of organic material (e.g. tobacco). Although metabolism is a fundamental requirement for their carcinogenicity (reviewed in Ref. 4) , their mutagenic properties are also subject to the activity of detoxification enzymes, such as the UGTs (5-7). Using benzo(a)pyrene 7,8-dihydrodiol as substrate, we observed a marked increase in UGT activity in liver microsomes from rats treated with ␤-naphthoflavone or oltipraz (4-methyl-5-pyrazinyl-3H-1,2-dithiole-3-thione (8)). A cDNA (clone LC14) was isolated from an adult rat hepatocytederived cell line encoding a UGT active in the glucuronidation of 14 different benzo(a)pyrene metabolites, including 7,8-dihydrodiol (9) . Sequencing of LC14 revealed identity with the product encoded by the UGT1A7 locus 2 (3). UGT1A7 mRNA is markedly increased in rat liver by PAHs and oltipraz. An identical pattern of mRNA regulation is observed for UGT1A6 (3, 9, 11, 12) , the better known PAH-inducible UGT with activity toward 4-nitrophenol and other simple phenols but not benzo(a)pyrene phenols (13, 14) . Because PAHs and oltipraz are known to induce transcription of other metabolizing enzymes by mechanisms involving the arylhydrocarbon receptor and/or oxidative stress (15) (16) (17) , our findings suggest that UGT1A6 and UGT1A7 may each be under the control of cis elements implicated in these responses, i.e. the xenobiotic response element (XRE) for arylhydrocarbon receptor mediated effects and the antioxidant response element (ARE) for oxidative stress-associated effects. * This work was supported by National Institutes of Health NIEHS Grant 1R29ES07762. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The To characterize the mechanism of PAH inducibility of rat UGT1A6, Emi et al. (18) have cloned and characterized the UGT1A6 gene promoter. The structure of the transcription unit was unusual in that it was composed of six rather than the five exons that are typical of other UGT1 transcription units (2, 3) . A putative XRE with the core sequence characteristic of all known XREs, 5Ј-GCGTG-3Ј, was identified between Ϫ134 and Ϫ129 upstream from the transcriptional start site. This sequence was shown to be a functional XRE, mediating 9 -15-fold inducibility of a chloramphenicol acetyltransferase reporter enzyme. These observations suggest that this particular sequence motif underlies the in vivo regulation of UGT1A6 by PAHs.
In this paper, we describe a study aimed at characterizing the mechanism of the increase in steady state UGT1A7 mRNA level by PAH and oltipraz. Nuclear runoff data indicate that increased gene transcription is the primary mechanism of mRNA accumulation in response to these agents. Characterization and sequencing of the UGT1A7 promoter and 5Ј-flanking region indicated several differences from UGT1A6, including its basic exon composition, the existence of Ͼ30 transcription start points, and the absence of any functional XRE or AREs in its immediate 5Ј flanking sequence.
EXPERIMENTAL PROCEDURES
Materials-Rats used in this study were male Sprague-Dawley rats purchased from Harlan Laboratories (Indianapolis, IN). Animal handling and experimentation for this study were carried out with the approval of the Institutional Animal Care and Use Committee at Virginia Commonwealth University. ␤-Naphthoflavone and 3-methylcholanthrene were from Aldrich and Sigma, respectively. Oltipraz was from the Chemoprevention Branch, National Cancer Institute (Bethesda, MD). The rat genomic DNA library (in bacteriophage EMBL3 SP6-T7) was from CLONTECH (Palo Alto, CA Plasmids-pRUGT1.6 contains a 783-bp fragment from the 5Ј end (bases ϩ28 to ϩ810) of the UGT1A6 cDNA (8) . The plasmid p1.4XB contains a 1499-bp XhoI-BamHI fragment from the extreme 5Ј end of the bacteriophage clone RPT-6 inserted into the XhoI and BamHI sites of pSKϩ. The plasmid p2.0XB contains the 5Ј XhoI-BamHI fragment of VIP-14 cloned into XhoI-BamHI cut pSKϩ. pLC14 (ϩ9/ϩ697) corresponds to a 690-bp fragment from the 5Ј end of the LC14 (UGT1A7) cDNA cloned into pCR2.1 (Invitrogen, Carlsbad, CA). pRBA-6 is a pCR2.1-based plasmid containing a 597-bp fragment of the rat ␤-actin cDNA amplified from rat liver cDNA using primers 5Ј-AGA CTA CCT CAT GAA GAT CCT GAC C-3Ј and 5Ј-GGA CTG TTA CTG AGC TGC GTT TTA C-3Ј, respectively. p340XP is a pSKϩ based plasmid containing the 340-bp XbaI-PstI fragment from p1.4XB. pHCYP1A1B5 represents the 5Ј BamHI fragment of the human CYP1A1 cDNA (including 18-bases of the 5Ј untranslated region, the complete 1563-base open reading frame, and 130 bases of the 3Ј untranslated region) (8) .
The base luciferase vector for construction of all chimeric UGT1A7-luciferase reporter plasmids was pGL3-Basic (Promega). p-965/ϩ56 1A7-Luc and pϩ56/-965 1A7-Luc were generated by cloning the 1.0-kbp PvuII fragment of p1.4XB into the SmaI site of pGL3-Basic in the correct and reverse orientations, respectively. p-1600-/ϩ56-UGT1A7 Luc, containing an additional 600-bp 5Ј extension of the UGT1A7 5Ј flanking region, was obtained by blunt-end cloning the 5Ј most PvuII fragment from p2.0XB into the SmaI site of pGL3-Basic. pSTM11 was a gift from S. McGill and Dr. R. Prough (Louisville, KY) and was derived by cloning the 1.1-kb HindIII-EcoRI fragment from the 5Ј flanking region of UGT1A6 into pGL3-Basic.
UGT1A7/UGT1A6 Promoter Cloning-A rat genomic DNA library (1 ϫ 10 6 independent plaque-forming units) was first screened using Escherichia coli K802 as the host strain and pRUGT1.6 insert labeled to high specific activity (Ͼ1 ϫ 10 9 dpm/g) by random hexamer priming as described, yielding clones RPT6, RPT12, and RPT19. One of these, RPT6, also hybridized with a probe prepared from pLC14 (ϩ9/ϩ697).
The library was rescreened using the pLC14 ϩ9/ϩ697 insert as probe, but a large number of clones were hybridized. These clones appear to correspond to UGT1A7-like exons. To narrow the number, the filters were rehybridized using a probe prepared from the EcoRV-EcoRI fragment flanking the UGT1A6 locus, yielding phage clone VIP-14. Largescale phage DNA purification was carried out as recommended by CLONTECH. The nucleotide sequence of a 1.4-kbp XhoI-BamHI fragment from RPT-6 was determined using the dideoxy chain termination method with a commercially available kit (Sequenase TM , U.S. Biochemical Corp.) and custom-made oligonucleotide primers.
RNA Isolation and Primer Extension Analysis-Total RNA was isolated by the acid phenol method (19) from livers of rats receiving either vehicle alone (1 ml/kg 30% polyethylene glycol-1450 (v/v) for 3 days), oltipraz (90 mg/ml, 300 mg/kg/day for 3 days), or ␤-naphthoflavone dissolved in corn oil (12 mg/ml, 80 mg/kg/day for 3 days). Poly(A)ϩ RNA was extracted by cellulose poly(dT) affinity chromatography (Boehringer Mannheim,). Two non-overlapping UGT1A7 antisense primers (6.375 and 6.376) were end-labeled with 32 P using [␥-32 P]ATP and T4 bacteriophage polynucleotide kinase to Ն1 ϫ 10 9 dpm/g and purified by centrifugation through Chroma Spin columns (CLONTECH). Primers (Ϸ1 ϫ 10 5 dpm/assay) were hybridized to poly(A)ϩ RNA (10 g) from each group for 16 h at 42°C in 40 mM PIPES, 1 mM EDTA, 0.4 M NaCl, and 40% formamide. The primer-annealed RNA was then precipitated and dissolved in 1 l of deionized water prior to extension using AMV-reverse transcriptase (25 units, Promega) in 10 l of 1ϫ AMV-reverse transcriptase buffer (Promega) containing 0.2 mM each dNTP, RNasin (20 units, Promega), and 0.5 g of actinomycin D. The products were analyzed on a 7 M urea, 8% polyacrylamide sequencing gel.
RNase Protection-A 32 P-labeled riboprobe corresponding to the antisense strand of the sequence between the XbaI and PstI sites (positions Ϫ337 and ϩ12 with respect to the UGT1A7 translation start) was synthesized in a reaction containing NotI-linearized p340XP (0.25 g), 1ϫ riboprobe synthesis buffer (supplied by Promega), 10 mM dithiothreitol, RNAsin (20 units), ATP/GTP/UTP (5 mM each), [␣- 32 P]CTP (50 Ci, 12 M), and T7 RNA polymerase (20 units, Promega) in a total volume of 20 l for 60 min at 37°C. The reaction was treated with RQ1 DNase (2 units, Promega) for 30 min, and the riboprobe was purified by centrifugation through a spin column (5Ј 3 3Ј, Inc., Boulder, CO). Riboprobe (5 ϫ 10 5 cpm) was mixed with yeast tRNA, control rat liver RNA, or oltipraz-treated rat liver RNA (10 or 50 g) in 50 l containing 40 mM PIPES, 1 mM EDTA, 0.4 M NaCl, and 40 or 80% formamide. The samples were treated with 300 l of RNase (300 mM NaCl, 10 mM Tris-Cl, pH 7.4, 5 mM EDTA, 2 g/ml RNase T1, 40 g/ml RNase A) for 30 or 60 min. After digestion with proteinase K (100 g/tube), the products were phenol-extracted and ethanol-precipitated prior to analysis on a 7 M urea, 8% acrylamide, 0.5ϫ Tris-borate-EDTA gel.
Nuclear Runoff Assays-The procedure used for hepatic nuclei isolation was based on that of Lee et al. (20) . Adult male Sprague-Dawley rats (n ϭ 3/group) were euthanized 12 h after treatment with a single dose of either vehicle (30% polyethylene glycol-1450, 3 ml/kg, intragastric), oltipraz (90 mg/ml suspension, 3 ml/kg, intragastric), or ␤-naphthoflavone (12 mg/ml in corn oil, 5 ml/kg, intraperitoneal). Livers were perfused in situ with 50 ml of ice-cold 0.9% saline and removed, and 3-g samples were minced into small pieces with scissors in 3 volumes of 0.3 M sucrose in Buffer A (15 mM Tris-HCl, pH 7.4, 15 mM NaCl, 60 mM KCl, 2 mM EDTA, 1 mM dithiothreitol, and 0.5 mM phenylmethylsulfonyl fluoride). After a brief homogenization using a Polytron homogenizer (set on low speed), samples were completely homogenized in 50-ml Potter-Elvjeham glass homogenizing tubes with a drill-driven Teflon pestle (three passes), and nuclei were then isolated by sucrose gradient centrifugation as described. The final nuclear pellet was suspended in 50 mM Tris-HCl, pH 7.4, 1 mM EDTA, 1 mM dithiothreitol, and 40% glycerol, and stored in aliquots of 200 l at Ϫ70°C. Nuclei concentrations were between 20 and 26 ϫ 10 6 nuclei/200 l. For nuclear runoff assays, nuclei were thawed, mixed with 50 l of a 5ϫ buffer containing 25 mM Tris-Cl, pH 7.5, 12.5 mM MgCl 2 , 0.75 M KCl, 12.5 mM dithiothreitol, 2.5 mM each of ATP, CTP, and GTP, 100 Ci [ 32 P]UTP (800 Ci/mmol), and incubated at room temperature for 15 min. RQ1 DNase (10 units) was added, and reactions were incubated for an additional 5 min. Yeast tRNA (50 g) was then added, and labeled nascent RNA was isolated by the method of Fei and Drake (21) . RNA (8 ϫ 10 6 cpm) was hybridized to Nytran membranes containing 5 g of immobilized, XhoIlinearized pRBA-6, pHCYP1A1B5, pLC14 ϩ9/ϩ697, and pSKϩ in 7 ml of 10 mM Tris-ethane sulfonic acid, pH 7.4, 10 mM EDTA, and 0.2% SDS for 48 h at 65°C. Membranes were washed and exposed to film (7-day exposure at Ϫ80°C with medium intensifying screen) and then to a Molecular Dynamics phosphorimaging cassette (1 day). Exposure were quantified using ImageQuant software (Molecular Dynamics, Sunnyvale, CA).
Northern Analyses-Northern analyses of total RNA isolated from liver tissue (0.3 g) or primary rat hepatocytes (8 ϫ 10 6 cells/100-mm dish) was carried out as described (8) . Probes were prepared from DNA inserts purified by low melting point agarose electrophoresis and labeled with [␣-32 P]dCTP by random priming (22) . (8 ϫ 10 5 ) isolated from collagenase-perfused livers of male SpragueDawley rats were plated on gelatin-coated plastic tissue culture dishes (35 mm), and 6 h later, the medium was removed and cells were washed once with serum-free medium (Williams E containing 0.6 g/ml insulin, 100 g/ml transferrin, 1 M dexamethasone, fungizone, and gentamicin). Lipofectin TM (7.5 g/dish) mixed with reporter plasmid (1.5 g) in 1.5 ml of serum-free medium was then added to the plate. After overnight (Ն12 h) incubation in a humidified, 5% CO 2 atmosphere, the medium was removed and replaced with fresh serum-free medium containing the inducing agents at the indicated concentration. Twentyfour h later, the medium was again removed and replaced with fresh inducer-containing medium. Cells were harvested at 48 h following the start of drug treatment. Luciferase activity was measured using the Luciferase Assay System (Promega) and a Berthold Lumat LB9501 luminometer.
Transient Transfection of Primary Rat Hepatocytes-Hepatocytes

RESULTS
Effect of Oltipraz and ␤-Naphthoflavone on the Rate of UGT1A7 Transcription-To investigate the mechanism of the inducer-associated increases in liver UGT1A7 mRNA level, nuclear runoff assays were carried out using nuclei isolated from rats 12 h after treatment with vehicle (30% polyethylene glycol), 250 mg/kg oltipraz or 80 mg/kg ␤-naphthoflavone. The Northern analysis of ␤-actin, cytochrome P4501A, and UGT1A7 transcripts at this time point is shown in Fig. 1A . Quantitation by phosphorimaging showed that oltipraz and ␤-naphthoflavone elevated the CYP1A mRNA 10-and 173-fold, respectively, and the UGT1A7 mRNA 19-and 43-fold. ␤-actin RNA levels were only slightly affected (2.5-and 2.8-fold for oltipraz and ␤-naphthoflavone, respectively).
A representative autoradiograph from a nuclear runoff assay (using nuclei from animals 2, 6, and 8) is shown in Fig. 1B . In the vehicle control, the rate of ␤-actin mRNA synthesis was the highest of the three mRNAs assayed and was not affected by either oltipraz or ␤-naphthoflavone treatment. In contrast, transcriptional rates of CYP1A and UGT1A7 were significantly increased by each agent. When signal intensities were corrected for background binding to vector alone, the oltipraz and ␤-naphthoflavone treatments produced increases of 4.4-and 29-fold for CYP1A1 and 3.7-and 8.4-fold for UGT1A7, respectively (Fig. 1C) . Similar results were obtained in a second nuclear runoff analysis using nuclei from animals 3, 5, and 9. These results indicate that the increases in mRNA level are due primarily to increased rates of mRNA synthesis.
Isolation and Sequencing of the LC14 Unique Exon and Identification as UGT1A7-To learn more about the mechanism(s), we isolated four genomic DNA clones from the UGT1A7/ UGT1A6 locus using 5Ј fragments of the UGT1A6 and/or LC14 cDNAs as probes as described under "Experimental Procedures." The overlap relationships of these clones (designated RPT6, RPT12, RPT19, and VIP14) was determined by restriction site mapping of XhoI, BamHI, and EcoRI sites ( Fig.  2A) together with Southern analysis. Two of the clones, RPT6 and VIP14, hybridized with both the UGT1A6 and LC14 probes. Together the cloned inserts form a contig of Ϸ27 kb. A detailed restriction map is included in Fig. 2B to establish the identity of the DNA investigated in this study. In agreement with the report of Emi et al. (3) , the UGT1A6-amino-terminal coding exon was localized to a 5.1-kbp internal EcoRI fragment of RPT6 immediately 5Ј of two small EcoRI fragments (0.5 and 0.9 kb). The UGT1A6* leader exon was localized by the presence of HindIII, PvuII, and HindIII sites 2 kb 5Ј, 0.1 kb 5Ј, and 0.3 kb 3Ј of the EcoRI site in the exon, respectively (Fig. 2B) .
The UGT1A7 exon was localized in clones RPT6 and VIP14 by Southern analysis with pLC14 (ϩ9/697) insert, which revealed an exon with an internal BamHI site mapping 1.4 and 2.0 kb from the termini of RPT6 and VIP14, respectively. Consistent with its identity as the LC14 origin, the exon also contained a PvuII and a PstI site 0.25 and 0.44 kb, respectively, upstream of the BamHI site. To establish this conclusively, the 1.4-kb XhoI-BamHI fragment at the terminus of RPT-6 was cloned (p1.4XB) and sequenced ( Fig. 3; 1499 bp  total) . The 3Ј-486-bp sequence extending from the BamHI site were identical to the LC14 5Ј end.
Determination of UGT1A7 Transcription Start Point-To define the UGT1A7 transcription unit, we carried out primer extension and RNase protection experiments. For primer ex-FIG. 1. Northern blot and nuclear runoff analyses of livers from oltipraz-and ␤-naphthoflavone-treated rats. Rats (three per group) received a single dose of vehicle, vehicle containing oltipraz, or ␤-naphthoflavone as described under "Experimental Procedures," and 12 h later, liver RNA and nuclei were prepared for Northern analysis or nuclear runoff analysis. A, Northern analysis of ␤-actin (pRBA-6), CYP1A (pHCYP1A1B5), or UGT1A7 (pLC14 (ϩ9/ϩ697)) mRNAs. Lanes 1-3, control (vehicle-treated); lanes 4 -6, oltipraz; lanes 7-9, ␤-naphthoflavone. B, nuclear runoff assay. Analysis of hepatic nuclear transcription rates was performed as described. The data correspond to tension, two antisense primers, 6.375 and 6.376, with an offset of 32 bases, were utilized for analysis of poly(A)ϩ RNA from the livers of vehicle-, oltipraz-, and ␤-naphthoflavone-treated rats. The results are presented in Fig. 4 . As expected, the products were only visible in samples from inducer-treated animals, especially with ␤-naphthoflavone. In these samples, similar ladders of extension products with the expected length differential of 32 bases were seen. In both reactions, the longest product maps to a guanosine residue at position Ϫ85 from the translation start codon. This residue is designated as base ϩ1 in Fig. 3 and maps 11 bases upstream of the first base in one of the cDNA clones isolated from RALA255-10G LCS-3 cDNA library (clone LC11).
To determine whether the multiple bands corresponded to multiple transcription start points or were due to artifacts in the extension reaction, we carried out RNase protection analysis using a radiolabeled riboprobe corresponding to the region between the XbaI and PstI sites at Ϫ337 and ϩ12 with respect to the start of translation. The results are shown in Fig. 5A . A ladder of bands corresponding to more than 30 different protection products were observed in all the lanes with oltipraztreated RNA samples, whereas relatively few bands were detected in the vehicle sample. Using a T3-primed pSKϩ sequencing reaction to estimate the 5Ј site of initiation, we observed a good correlation between the data generated by primer extension analyses and RNase protection (Fig. 5B) including bases where transcription is initiated and their relative intensity (abundance). Five distinct clusters of start sites between the guanosine at Ϫ85 and a cytosine at Ϫ40 were evident in the oltipraz sample, with the major cluster being group D. In the control rat sample, start sites in group D also predominated, with a few detected in group C and none in the remaining clusters. These results strongly suggest that multiple transcription start points are utilized for rat UGT1A7 transcription. They also show conclusively that transcription begins in a region immediately flanking the UGT1A7 coding exon and rule out the existence of a noncoding UGT1A7 leader exon exon analogous to UGT1A6* (Fig. 2) .
In view of the proximity of UGT1A7 and UGT1A6 and their common regulation, it was of interest to compare the sequences of the two promoter regions. No obvious tracts of homology or identity were observed in the proximal promoter region (only bases Ϫ400 to Ϫ1 of the UGT1A6 promoter were reported). The low identity is consistent with the low overall similarity of the FIG. 4 . Primer extension analysis of UGT1A7 mRNA. Two nonoverlapping UGT1A7 antisense primers (6.375 and 6.376) were endlabeled with [␥-32 P]ATP and used for primer extension analysis of poly(A)ϩ RNA from control ( lanes 1 and 4) , oltipraz-treated (lanes 2 and 5), and ␤-naphthoflavone-treated (lanes 3 and 6) rats as described under "Experimental Procedures." The sequence ladders shown were generated using the indicated primers and p1.4XB as template. The groups of products corresponding to each other and to the RNase protection products in Fig. 5 are indicated (A-E) .
FIG. 5.
RNase protection analysis of UGT1A7 mRNA. A, RNase protection analysis using an antisense riboprobe spanning from Ϫ337 (XbaI) to ϩ12 (PstI) with respect to the start of translation was performed as described under "Experimental Procedures." The sequencing ladder corresponds to the pSKϩ multiple cloning region using T3 as primer. B, correspondence between initiation sites predicted by primer extension and RNase protection. Initiation sites predicted from primer extension with primers 6.375 or 6.376 (data from lanes 3 and 6 of Fig.  4 ) and RNase protection were determined and assigned relative signal intensities of 0 (not detectable), 1 (weak but detectable), 2 (intermediate), or 3 (strong). The plot shows the additive scores for each nucleotide position (maximum score ϭ 9).
UGT1A6 and UGT1A7 amino-terminal sequences, indicating a fairly distant evolutionary relationship. Similar to UGT1A6, however, UGT1A7 contains sequences closely matching known CCAAT enhancer-binding protein and hepatic nuclear factor 3-binding sites (Fig. 3) .
Induction of UGT1A7 and CYP1A mRNA in Primary Cultures of Rat Hepatocytes-Analysis of the mechanism(s) of the inducer-mediated increases in UGT1A7 transcription requires an appropriate cellular model. Previous studies carried out with an immortalized SV40-transformed adult rat hepatocyte cell line (RALA LCS) indicated high constitutive UGT1A7 mRNA expression compared with in vivo expression. Fig. 6 compares the in vivo and in vitro responses to Ah receptor agonists and oltipraz at the level of mRNA. The low constitutive expression of UGT1A7 mRNA observed in vivo in livers of untreated rats (Fig. 6, lane 4) is maintained in untreated primary rat hepatocytes (lane 1). Treatment with aryl hydrocarbon receptor agonists and with oltipraz leads to a strong stimulation of UGT1A7 mRNA both in vivo (Fig. 6, lanes 6 and 5, respectively) and in primary hepatocytes (lanes 2 and 3, respectively). ␤-Actin mRNA was highly expressed both in vivo and in hepatocytes in vitro but was not affected by either treatment. Some qualitative differences were observed in the constitutive expression and inducibility of the CYP1A RNAs as detected using the human CYP1A probe. Compared with in vivo, oltipraz was not as effective at inducing the CYP1A1 and CYP1A2 mRNAs in primary hepatocytes in vitro. Overall, the data lend support for the usefulness of primary rat hepatocytes as a cellular model for investigating mechanisms of UGT1A7 transcriptional control.
Effect of 3-Methylcholanthrene and Oltipraz on Luciferase Expression
Controlled by UGT1A7-The above studies predicted that the DNA flanking the UGT1A7 exon should act as an orientation-dependent promoter with cis regulatory elements controlling UGT1A7 transcription. To investigate this, an XhoI-PvuII fragment of RPT-6 corresponding to bases Ϫ965 to ϩ56 was cloned in either orientation upstream of the luciferase reporter gene of pGL3-Basic, and the resulting constructs were transfected into primary rat hepatocytes. Lysates of cells transfected with the promoter fragment in the correct orientation exhibited more than 50-fold higher luciferase activity than cells transfected with the reverse construct. The activity was not affected by oltipraz treatment, but it was increased 2-3 fold by 3-methylcholanthrene (Fig. 7A) . Similar results were observed for a reporter plasmid containing a 660-base 5Ј extension (p-1600/ϩ56 1A7-Luc). However, the base luciferase vector itself (pGL3-Basic) yielded Ϸ3-fold inducibility by 3-methylcholanthrene (Fig. 7B) . Similar "inducibility" was observed with pGL3-Promoter plasmid (data not shown), suggesting that the 3-methylcholanthrene responsiveness is not dependent on the UGT1A7 sequence but rather on a sequence present in the vector itself. In contrast, experiments with hepatocytes transfected with an analogous pGL3-based UGT1A6 luciferase reporter plasmid (pSTM11) showed much greater responsiveness to 3-methylcholanthrene; unlike p-965/ ϩ56 1A7 Luc, pSTM11 was responsive to oltipraz.
DISCUSSION
Work in two different laboratories now conclusively supports the existence of two different PAH-and oltipraz-inducible forms of UDP-glucuronosyltransferase in rat liver (3, 9, 18, 23) . The two forms are encoded by the UGT1A6 and UGT1A7 loci and have distinct substrate specificities toward planar phenols. Given the close physical proximity of the two loci and the many 
FIG. 7.
Effect of 3-methylcholanthrene and oltipraz on expression of luciferase in primary rat hepatocytes transfected with various luciferase reporter plasmids. Primary rat hepatocytes (three dishes/group) were transfected with the indicated luciferase reporter plasmid and exposed to vehicle, oltipraz, or 3-methylcholanthrene as described in the text. Cells were harvested 48 h after the start of drug treatment, and luciferase activity was determined. The data represent the mean Ϯ S. D. of three independent determinations. A, data presented in absolute terms. B, data presented in relative terms (percentage of the mean of corresponding vehicle). parallels in their patterns of mRNA expression (e.g. repressed constitutive expression and high inducibility by both PAHs and oltipraz), we expected that the genes would share certain characteristics involving exon structure and organization and transcriptional initiation. Instead, key differences between the two PAH-regulated UGT genes stand out.
One difference involves the total number of exons composing the complete transcription unit of each gene: six exons for UGT1A6 and five for UGT1A7. The difference lies in the number of exons coding for the unique 5Ј sequence of each respective mRNA. UGT1A6 uses two exons for this purpose, including a short 142-bp non-coding leader exon (labeled UGT1A6* in Fig. 2 ) and a longer exon containing the first 845 bp of the UGT1A6 coding region (labeled UGT1A6 in Fig. 2 ). Our primer extension and RNase protection data demonstrate that UGT1A7 differs from UGT1A6 in utilizing only a single exon to code for its entire unique 5Ј terminal sequence. This arrangement predicts that the DNA flanking the long UGT1A7 unique amino-terminal-coding exon functions as a gene promoter. In accordance with this, a fragment representing bases Ϫ965 to ϩ56 of UGT1A7 promoter drove high expression of a downstream luciferase reporter when inserted in the correct (5Ј-3Ј) but not the reverse (3Ј-5Ј) orientation. UGT1A7, therefore, possesses the 5 exon structure that is more typical of UGT1 genes such as UGT1A1, UGT1A4, and UGT1A6 3 (2). Another key difference between the UGT1A6 and 1A7 loci is the utilization by UGT1A7 of a complex of transcription start sites, clustered in a 45-bp region between 85 and 40 bases upstream of the translation start codon. Regardless of the site of initiation within this cluster, all transcripts are predicted to encode the full-length UGT1A7 protein, with the first AUG codon being the normal translation start site of UGT1A7. The basis for this heterogeneous initiation appears to be related to the lack of an efficient TATA box to direct precise transcriptional initiation. The region flanking the complex of transcription sites is enriched in TA residues, which are postulated to serve as weak TATA factor binding sites. The UGT1A7 promoter does not appear to be TATA-independent (housekeeping type) because there are no Sp1-binding sites and the promoter region overall is low in GC dinucleotide content. Furthermore, similar to other TATA-dependent genes, UGT1A7 possesses a sequence in its near upstream region closely matching a functional CCAAT enhancer-binding protein in the rat apolipoprotein B gene (24) . The lack of a strong transcriptional initiating sequence may account for the lower relative abundance of UGT1A7 mRNA compared with UGT1A6 in livers of PAH-and oltipraz-treated rats (9) and the low or undetectable expression of UGT1A7 mRNA in human liver samples (25) .
One major goal of research is to identify transcription factors regulating the expression of rat UGT1A7, because variation in such factors may underlie variability in UGT1A7 expression and thereby alter individual susceptibility to PAH-associated toxicities. The UGT1A7 promoter contains sequences closely matching (Յ2 mismatches) known functional or consensus binding sites for hepatic nuclear factor 1 (rat glutathione Stransferase Ya gene) (26) , hepatic nuclear factor 3, hepatic nuclear factor 4 (27) , and activator protein 1. Further analysis is necessary to determine whether these sites are functionally involved in the control of UGT1A7 gene expression. Computeraided inspection of the sequence failed to uncover any close matching ARE or XRE sequences; these elements were previously implicated in the regulation of other phase 1 and/or phase 2 metabolizing enzymes by PAHs (15, 18) and oltipraz (16) . Consistent with these negative findings, no PAH or oltipraz inducibility (above the 2.5-fold level observed with the control luciferase vector) was conferred by the UGT1A7 promoter and 5Ј flanking sequence. Clearly, UGT1A7 lacks an XRE in an analogous position to that of UGT1A6.
Because the nuclear runoff assays indicate that the effects of PAHs and oltipraz on UGT1A7 mRNA are due primarily to transcriptional activation, the data suggest that the cis elements mediating this activation are located either 5Ј or 3Ј of the region studied in this report. One possibility is that the inducibility of UGT1A7 is controlled by the XRE located 7 kb downstream in the UGT1A6 promoter region. This model is attractive because it could explain the concordant patterns of UGT1A6/UGT1A7 expression in various species. In mice and rabbits (and apparently humans), expression of both UGT1A6 and UGT1A7 is high in the constitutive state, and each is relatively refractory to inducing agents (28, 29) . In rats, both UGT1A6/1A7 have low constitutive expression and are highly responsive to the inducing agents. The loss of transcriptional inducibility of two genes, UGT1A6 and 1A7, is most simply explained by a mutation involving only a single regulatory element. Another possibility, however, is that their inducibility by PAHs or oltipraz does in fact occur through distinct regulatory elements. We are currently testing the intronic region of the UGT1A7 gene for evidence of inducer-responsive enhancers or repressors.
In contrast to PAHs, the sequence mediating the responsiveness of UGT1A6/1A7 to oltipraz remains unknown. Our transient transfection analysis with the UGT1A6 luciferase reporter provides the first evidence that the UGT1A6 promoter flanking sequence contains oltipraz-responsive transcriptional enhancer elements. It is not clear whether this element corresponds to the XRE element previously identified by Emi et al. (3) or some other sequence motif (i.e. ARE). Evidence is appearing that oltipraz or perhaps one of its metabolites may be a weak activator of the arylhydrocarbon receptor (30) . These findings are further supported by our study, showing transcriptional stimulation of CYP1A genes and increased CYP1A1/1A2 mRNA levels following oltipraz treatment in vivo and in rat hepatocytes in vitro.
